High Q is a private philanthropic foundation dedicated to finding therapies for Huntington's disease (HD). Over the past seven years High Q and its affiliates have committed more than $50 million to HD research directly and through organizations such as the Hereditary Disease Foundation (HDF), the Huntington's Disease Society of America (HDSA), and the Huntington Study Group (HSG). Now High Q has established an independent presence in order to bring together academia, industry, governmental agencies, and other funding organizations to accelerate the search for HD therapies.

Among the projects High Q and its affiliates have funded is the HDF's Cure HD Initiative (CHDI), created seven years ago to bring a fast-track industrial approach to the translation of HD research from the laboratory to the clinic. Since then this initiative has grown to comprise some 130 projects with over $30 million of support. High Q supports HD clinical research through the Huntington Project  which includes a systematic evaluation of treatments for Huntington's Disease (SET-HD). Last fall it was chartered as an independent public charity, called CHDI, Inc., which is supported primarily by High Q. CHDI, Inc. operates as a not-for-profit, virtual biotech company devoted to drug discovery and development for HD.